GlassScriptPhysician profile
Mary E Klunick
NPI 1083130298
$4,298.23
in general payments reported to CMS, 2019-2025
16 companies · $788 in 2025
The $788 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $584 · 2022: $1,540 · 2023: $627 · 2024: $760 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.59 |
| Education | $111.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,189.06 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $859.65 | 2021-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $269.07 | 2021-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.88 | 2021-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $182.76 | 2025 | Rezdiffra |
| Janssen Scientific Affairs, LLC | $153.92 | 2021-2022 | |
| Lilly USA, LLC | $123.26 | 2024 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $61.88 | 2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $60.16 | 2022 | |
| Intercept Pharmaceuticals, INC. | $46.21 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $37.23 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $28.71 | 2022 | |
| Braintree Laboratories, INC. | $18.94 | 2023 | Sutab, Suflave |
| Ardelyx, INC. | $15.27 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $13.84 | 2025 | Zenpep |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Klunick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.